# Alpha-Lipoic Acid Alpha-lipoic acid, often shortened to **ALA**, is a small sulphur-containing compound used in neuropathy research and care discussions. It is best understood as a nerve-supportive antioxidant and mitochondrial co-factor. It is not a guaranteed fix. It is also not the same thing as proven metal detox. ### Jump to * [What it is](#what-it-is) * [How it might help nerves](#how-it-might-help-nerves) * [Where the evidence is strongest](#where-the-evidence-is-strongest) * [Where the evidence is weaker](#where-the-evidence-is-weaker) * [Practical and safety notes](#practical-and-safety-notes) * [Bottom line](#bottom-line) * [Key references](#key-references) ### What it is ALA has been used for years in Europe, especially in diabetic neuropathy care. The main symptoms studied are burning, tingling, numbness, and nerve pain in the feet. Within this documentation set, ALA is best framed as one possible tool inside a broader nerve-care plan. That broader plan usually includes: * blood-sugar stability * nutrition and micronutrient support where needed * movement and safety work * sleep and nervous-system support ### How it might help nerves Several mechanisms are proposed. #### Antioxidant support ALA appears to reduce oxidative stress around nerves. It may also help regenerate or support the body's own antioxidant systems, including glutathione, vitamin C, and vitamin E. That matters because oxidative stress is one of the recurring themes in both diabetic and treatment-related nerve injury. #### Mitochondrial support ALA acts as a mitochondrial co-factor. That means it may help nerve cells with energy production. This is one reason it is discussed in neuropathy rather than only in glucose metabolism. #### Microcirculation support In diabetic neuropathy, ALA has been linked to improved microcirculation and nitric-oxide-mediated vasodilation. That may help support blood flow to small nerve fibres. #### Pain-signalling effects Preclinical work suggests ALA may dampen inflammatory signalling and some pain-sensing pathways. That could help explain why some people report less burning or shooting pain. ### Where the evidence is strongest The strongest human evidence is in **painful diabetic neuropathy**. Repeated trials suggest ALA can improve symptom scores, especially for pain, tingling, and numbness. The most commonly studied dose is **600 mg per day**. Some studies used **intravenous ALA for 2 to 3 weeks**. Others followed with oral dosing. Some studies also report improvement in: * clinical impairment scores * nerve conduction measures * multi-symptom neuropathy scales A more recent randomised trial found that **600 mg oral ALA once daily for 12 weeks** improved several neuropathy symptom measures in people already taking **gabapentin** or **pregabalin**. That makes the evidence more relevant to real-world combination care. ### Where the evidence is weaker #### Chemotherapy-induced peripheral neuropathy Evidence here is much thinner. Results are mixed. A lot of the enthusiasm comes from: * diabetic neuropathy trials * preclinical oxidative-stress models * mitochondrial-injury logic in chemotherapy-damaged nerves That is useful context. It is not the same as strong clinical proof in chemotherapy-induced neuropathy. #### Metal-detox claims ALA can bind metals in laboratory settings. That does not mean neuropathy benefit in humans comes from clearing platinum or other metals out of nerves. Human neuropathy studies mainly support antioxidant, mitochondrial, and circulation-related explanations. #### Longer-term progression prevention Some longer studies suggest stabilisation or partial benefit. The signal is not consistent. A 2024 Cochrane review concluded that ALA probably has little or no effect on neuropathy symptoms at six months compared with placebo. That does not mean ALA never helps. It means the benefit is not universal, and expectations should stay realistic. ### Practical and safety notes {% hint style="warning" %} ALA should not be added quietly in the background during active cancer treatment. Review it with the oncology team, pharmacist, and GP first. {% endhint %} Common practical points include: * neuropathy studies often use **600 mg per day** * use is usually **time-limited** rather than open-ended * gastrointestinal side effects can include nausea or reflux * rash can occur * blood-sugar lowering can matter, especially in people already using glucose-lowering medication Rare hypoglycaemia has been reported. ALA may also interact with: * diabetes medications * thyroid medication * selected chemotherapy or targeted therapies That interaction question matters more than many people expect. ### Bottom line ALA is a plausible adjunct for neuropathy support. Its best evidence is in diabetic neuropathy, not chemotherapy-induced neuropathy. For some people, it may help with pain, tingling, or numbness. For others, it may do very little. The most useful way to think about it is as one option inside a broader nerve-support plan, not as a stand-alone answer. ### Key references * [Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features](https://pmc.ncbi.nlm.nih.gov/articles/PMC9774895/) * [Alpha-Lipoic Acid: Its Antioxidant and Anti-Inflammatory Role and Clinical Applications](https://pmc.ncbi.nlm.nih.gov/articles/PMC2836194/) * [Effects of Alpha-Lipoic Acid in the Treatment of Diabetic Neuropathy: A Systematic Review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10627688/) * [Alpha-Lipoic Acid and Diabetic Neuropathy: From Pathophysiology to Evidence-Based Therapy](https://pmc.ncbi.nlm.nih.gov/articles/PMC11302972/) * [Oral Treatment With Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy](https://diabetesjournals.org/care/article/29/11/2365/24539/Oral-Treatment-With-Lipoic-Acid-Improves) * [Therapeutic efficacy of alpha lipoic acid compared to pregabalin and gabapentin in painful diabetic neuropathy](https://pmc.ncbi.nlm.nih.gov/articles/PMC11513224/) * [Alpha-lipoic acid for peripheral neuropathy](https://www.cochrane.org/evidence/CD012967_alpha-lipoic-acid-natural-antioxidant-better-no-treatment-or-dummy-treatment-nerve-damage-people) * [Alpha-Lipoic Acid - StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK564301/) * [Alpha-Lipoic Acid: Uses and Risks](https://www.webmd.com/vitamins/ai/ingredientmono-767/alpha-lipoic-acid) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/side-effects/peripheral-neuropathy-after-cancer-treatment/alpha-lipoic-acid.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.